<DOC>
	<DOC>NCT01596517</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy and effectiveness of peginterferon alfa-2a and ribavirin therapy in Korean chronic hepatitis C patients.</brief_summary>
	<brief_title>Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>A retrospective analysis of a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial of combination of peginterferon alfa-2a and ribavirin (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004 and a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>all of below adults aged 1870 years serum antiHCV antibody (+) HCV RNA detectable by PCR compensated liver disease (ChildPugh class A) any of below HCV genotype other than 1, 2, or 3 acute hepatitis C decompensated cirrhosis or hepatocellular carcinoma other liver disease such as hepatitis A or B, or autoimmune hepatitis HIV Ab(+) severe depression or other psychiatric disease previous organ transplantation absolute neutrophil count (ANC) &lt; 1,000 cells/mm3 or platelet count &lt; 75,000 cells/mm3, or hemoglobin (Hb) &lt; 13 g/dL for men, &lt;12 g/dL for women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>